2021
How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCare
2010
Enhancing Existing Approaches to Peripheral T-Cell Lymphoma
Foss FM. Enhancing Existing Approaches to Peripheral T-Cell Lymphoma. Seminars In Hematology 2010, 47: s8-s10. PMID: 20359584, DOI: 10.1053/j.seminhematol.2010.01.012.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaFirst-line therapyT-cell lymphomaNational Comprehensive Cancer Network practice guidelinesEffective first-line therapyStandard treatment optionSame treatment regimenB-cell lymphomaPTCL patientsTreatment regimenDenileukin diftitoxConventional therapyHistopathologic subtypeTreatment optionsNovel agentsPractice guidelinesLymphomaChemotherapy platformTherapyPatientsOutcomesDiftitoxRegimenTransplantSubtypes
2007
Cutaneous T-cell lymphoma: Biologic targets for therapy
Choi J, Foss F. Cutaneous T-cell lymphoma: Biologic targets for therapy. Current Hematologic Malignancy Reports 2007, 2: 272-277. PMID: 20425380, DOI: 10.1007/s11899-007-0037-8.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsApoptosisCD4 AntigensClinical Trials as TopicDiphtheria ToxinDrug Delivery SystemsDrug DesignEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansImmunologic FactorsImmunotherapyInterferon-gammaInterleukin-2Lymphoma, T-Cell, CutaneousNeoplasm ProteinsPhotopheresisRecombinant Fusion ProteinsSkin NeoplasmsT-Lymphocyte SubsetsTumor EscapeConceptsCutaneous T-cell lymphomaReceptor-dependent signaling pathwaysEpigenetic changesSignaling pathwaysClonal populationsSkin-homing lymphocytesT-cell lymphomaT cell activationPersistence of tumorHost immune systemCTCL cellsCancer immunosurveillanceImmune cellsLangerhans cellsCytotoxic phenotypeDisease pathogenesisBiologic targetsImmune systemCellsTherapyDiseasePhenotypePathwayImmunosurveillanceActivation
2003
Peripheral T- cell lymphomas: diagnosis and management
Dearden CE, Foss FM. Peripheral T- cell lymphomas: diagnosis and management. Hematology/Oncology Clinics Of North America 2003, 17: 1351-1366. PMID: 14710889, DOI: 10.1016/s0889-8588(03)00119-9.Peer-Reviewed Original ResearchConceptsFirst-line therapyT-cell lymphomaCampath-1HResponse rateLine therapyPurine analoguesT-PLLAllogeneic bone marrow transplantationPeripheral T-cell lymphomaThird of patientsFavorable prognostic factorBone marrow transplantationMonoclonal antibody therapyStem cell transplantationNon-randomized studiesMature T-cell neoplasmsMinimal residual diseaseT-cell neoplasmsHigh response rateT-cell malignanciesLargest disease groupRisk of toxicityDurable remissionsRefractory patientsPreparative regimens